Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Broker tips: Admiral, BAE Systems, Hipgnosis
(Sharecast News) - Insurer Admiral tanked on Tuesday after Citi downgraded its stance on the shares to 'sell', saying that a 'deep dive' into industry loss ratio trends had suggested that consensus estimates for the group are currently an outlier. "We downgrade Admiral to sell and issue a negative catalyst watch as we expect an earnings expectation reset and material downside risk into 1H23E numbers," Citi said.
The bank said it's 10% below both 1H23 and FY23 consensus earnings per share estimates.
Elsewhere, Morgan Stanley initiated coverage of BAE Systems with an 'overweight' rating and 1,208p price target, as it initiated coverage on the European defence sector.
The bank said BAE is its 'top pick' among the defence names.
"We believe the group is in the early phase of a multi-year upturn, driven by strong and consistent programme execution, rising global defence spending, and diverse positions on key growth programmes," it said.
"Our longer-term (2025-30) earnings forecasts are materially above consensus (6% CAGR versus 3% for consensus)."
MS said its conviction is driven by its bottom-up programme forecasts, which it thinks may be too conservative still.
"We do not believe the growth outlook is accurately reflected in the current valuation, with the shares trading in-line with their recent (1year) average and at a 10% discount to US peers.
"We think the shares deserve a higher rating. At our price target, the shares would trade on a P/E of 16x in 2025, in-line with US Defence Prime peers, which we think is justified given the group's diversified portfolio and long-term growth and shareholder returns outlook."
Morgan Stanley said it expects consistent execution and order activity to drive consensus expectations higher.
"The group has an attractive shareholder returns policy, with a dividend yielding 3% and an ongoing share buyback programme, which we think could be extended," it said.
The bank initiated coverage on the broader European aerospace and defence sector with an "attractive" view, as it said that with valuations near historical highs, earnings upgrades are key for further upside to European defence shares.
"We're defensive, preferring stocks with diversified exposures and where current expectations are not elevated," it said.
Jefferies upgraded Hipgnosis Songs Fund to 'buy', after the risk-reward dynamic for the music investment firm became "more favourable".
Jefferies - which previously had a 'hold' rating on the stock - said it saw potential for Hipgnosis to announce selective disposals, generating cash to repay debt and/or make share buybacks.
It continued: "To date, Hipgnosis has yet to make a single disposal. Relationships with the selling songwriters are clearly key, with the manager entrusted with the assets, rather than being a pure financial buyer.
"That said, the fund could still dispose of an institutional acquisition, like Kobalt Fund 1, consisting of 33,000 songs, acquired for $23m in 2020.
"Alternatively, [it] could potentially sell a minority strip of its entire portfolio, while maintaining control of its catalogues."
Jefferies concluded: "We see Hipgnosis's risk-reward dynamic as having become more favourable ahead of forthcoming results and subsequent continuation vote.
"Hipgnosis could attempt to appease shareholders by announcing plans to make portfolio disposals, providing a catalyst to help narrow its current deep 46% discount to net asset value. As such, we upgrade to 'buy'."
The firm is due to report final results on 31 July, following by an annual general meeting in the autumn, when its first continuation vote will be proposed.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.